Alcohol-associated liver disease predicts increased post-liver transplant opioid use

Clin Transplant. 2022 Dec;36(12):e14811. doi: 10.1111/ctr.14811. Epub 2022 Sep 19.

Abstract

Background: Alcohol-associated liver disease (ALD) is a rising indication for liver transplantation (LT). Prolonged opioid use after LT leads to increased graft loss and mortality. The aim is to determine if patients transplanted with a primary diagnosis of ALD had higher risk of post-LT opioid use (p-LTOU) compared to non-ALD patients.

Methods: This is a retrospective study of patients who underwent LT between 2015 and 2018 at Medstar Georgetown Transplant Institute. Patients with prolonged hospitalization post-LT (>90 days), death within 90 days post-LT, and re-transplants were excluded.

Results: Two hundred and ninety seven patients were transplanted, among 29% for indications of ALD. ALD patients were younger (52 vs. 56 years), more likely to be male (76% vs. 61%), Caucasian (71% vs. 44%), have higher MELD (28.8±8.8 vs. 25±8.8), and psychiatric disease than non-ALD patients (P < .05). There was no difference in pre-LT use of opioids, tobacco, marijuana, or illicit drugs between ALD and non-ALD patients. Pre-LT opioid use (OR = 11.7, P < .001), ALD (OR = 2.5, P = .01), and MELD score (OR = .95, P = .02) independently predicted 90-day p-LTOU.

Conclusions: ALD, pre-LT opioid use, and MELD score independently predict p-LTOU. Special attention should be paid to identify post-LT prolonged opioid use in ALD patients.

Keywords: alcoholism and substance abuse; liver disease; outpatient care; patient characteristics; risk assessment/risk stratification.

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Female
  • Humans
  • Liver Diseases, Alcoholic* / surgery
  • Liver Transplantation* / adverse effects
  • Male
  • Retrospective Studies

Substances

  • Analgesics, Opioid